Clinical Trials Logo

Clinical Trial Summary

Treating with measures that may improve metabolic functioning of neurons in an integrated protocol


Clinical Trial Description

Most organ failure results in modest drops in function until over 50% of function is lost. At a certain point, even modest drops in physiologic activity result in dramatic drops in clinical function. Though less homogeneous than in other organs, clinical experience and the literature suggests a similar process occurs in the brain. The hypothesis is that by using an integrated protocol to, essentially, "tune up" neuronal function, a 5-10 % improvement in metabolic functioning may translate to significant improvement in clinical functioning. This tune-up will include "MIND":

M- Metabolism-- optimizing hormonal function I- Infections-- looking for and eliminating N- Nutritional and herbal support D- Drugs- Weaning subjects off unneeded medications ;


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02260167
Study type Interventional
Source Practitioners Alliance Network
Contact Jacob E Teitelbaum, MD
Phone 410-562-7409
Email endfatigue@aol.com
Status Recruiting
Phase Phase 2
Start date September 2014

See also
  Status Clinical Trial Phase
Recruiting NCT03316898 - A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease Phase 1
Withdrawn NCT02860065 - CPC-201 Alzheimer's Disease Type Dementia: PET Study Phase 2
Active, not recruiting NCT02484547 - 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease Phase 3
Active, not recruiting NCT01315639 - New Biomarker for Alzheimer's Disease Diagnostic N/A
Terminated NCT03307993 - Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease Phase 1
Not yet recruiting NCT02359864 - Study of Low Dose Whole Brain Irradiation in the Treatment of Alzheimer's Disease N/A
Recruiting NCT02912936 - A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease Phase 1
Not yet recruiting NCT02868905 - Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women N/A
Not yet recruiting NCT02899091 - Evaluation of the Safety and Potential Therapeutic Effects After Intravenous Transplantation of CB-AC-02 in Patients With Alzheimer's Disease Phase 1/Phase 2
Completed NCT02907567 - Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease Phase 1/Phase 2
Recruiting NCT02547818 - Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease Phase 3
Recruiting NCT02580305 - SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study Phase 2
Recruiting NCT02521558 - Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease N/A
Completed NCT02516046 - 18F-AV-1451 Autopsy Study Phase 3
Recruiting NCT02247180 - Cognitive Rehabilitation in Alzheimer`s Disease N/A
Recruiting NCT02317523 - Alzheimer's Caregiver Coping: Mental and Physical Health N/A
Terminated NCT02220738 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors Phase 1
Completed NCT02256306 - The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study N/A
Completed NCT02309723 - How Beta-amyloid Imagining Influences Clinician Diagnosis and Management of Hypothetical Patients With Cognitive Complaints N/A
Completed NCT01826110 - PET Imaging Study Using [11C]PIB in Subjects With AD & Healthy Volunteers Phase 1